Sold by: OM1
Deployed on AWS
This product provides switching patterns between different biologic disease-modifying antirheumatic drugs (bDMARDs) during first, second, and third lines of bDMARD therapy. All patients in this dataset received treatment with adalimumab (Humira), the best-selling drug in the United States since 2012. Additional datasets and summaries - including focus on other drugs, additional lines of therapy, and specific time periods - are available upon request.
Overview
This product provides switching patterns between different biologic disease-modifying antirheumatic drugs (bDMARDs) during first, second, and third lines of bDMARD therapy. All patients in this dataset received treatment with adalimumab (Humira), the best-selling drug in the United States since 2012. Additional datasets and summaries - including focus on other drugs, additional lines of therapy, and specific time periods - are available upon request. For more information, visit <www.om1.com> and get in touch at info@om1.com .
Details
New
Introducing multi-product solutions
You can now purchase comprehensive solutions tailored to use cases and industries.
Features and programs
Financing for AWS Marketplace purchases
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
Pricing
Pricing is based on the duration and terms of your contract with the vendor. This entitles you to a specified quantity of use for the contract duration. If you choose not to renew or replace your contract before it ends, access to these entitlements will expire.
Additional AWS infrastructure costs may apply. Use the AWS Pricing Calculator to estimate your infrastructure costs.
Dimension | Cost/12 months |
|---|---|
ProductAccess | $999.00 |
Vendor refund policy
No refunds offered. For any questions, please e-mail us at info@om1.com .
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA) .
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Additional details
You will receive access to the following data sets.
Data set name | Type | Historical revisions | Future revisions | Sensitive information | Data dictionaries | Data samples |
|---|---|---|---|---|---|---|
Adalimumab drug switching in Rheumatoid Arthritis | All historical revisions | All future revisions | Not included | Not included |
Similar products
Machine Learning model to predict the Adverse Drug Reactions.
Engage in our BioLLM Acceleration program and transform the traditionally costly and protracted drug discovery process. Within 10-12 weeks, our experts build model architectures using BioLLMs such as Protein and DNA language models customized to your proprietary and expanded public datasets. By leveraging generative AI, we are able to exceed the limits of physical screening for bigger sampling and better candidate selection. Our work concludes with a comprehensive Proof of Concept (POC), model performance comparison, resulting model, intermediate datasets and more – paving the way for broader training initiatives and productization.
Drugs@FDA contains information about products approved by the FDA for human use in the United States since 1938
Enhance drug discovery with Loka’s Agentic Drug Discovery program, employing advanced AI technologies and intuitive chat interfaces for streamlined research workflows.
SoftServe Gen AI Drug Discovery Solution, fully deployed on AWS, and accelerated by NVIDIA BioNeMo™ Blueprints and AWS Services, speeds up drug discovery by enabling AI-powered molecule generation, screening, and optimization. Utilizing AI tools such as MolMIM, DiffDock, and SoftServe's proprietary molecular generator, the solution provides researchers with insights into successful drug candidate properties, optimizing the research process from lab to market.